Amgen (NASDAQ:AMGN) executives highlighted broad-based commercial momentum, a focus on long-term growth drivers, and several ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha (evolocumab) ...

Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug. One ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM ESTCompany ParticipantsKave Niksefat - Senior Vice President of ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

A brand-name drug is the original version of a medication that’s FDA-approved to treat a specific condition. Generics contain exact copies of the active ingredient in the original branded drug (an ...

The emergence of Lilly’s bundling strategy for Zepbound and Taltz reflects the unregulated state of patient assistance programs in the commercial market and the need for Congressional intervention.

John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Emory is the data editor at ...